9 mai 2025|
AI
|7 months agoSwiss Biotech Sector Sees Chinese Partnership Surge
Chinese companies seek Swiss collaboration amid US tensions, reshaping biotech landscape
AI
Generated IllustrationKey Takeaways
AI
- Swiss Biotech Day in Basel saw a record-breaking 3,000 participants.
- China is now the largest developer of antibody drug conjugates (ADCs).
- Novartis is constructing a $100 million factory for radioligand cancer therapy in China.
- Roche signed a deal worth up to $1 billion with Chinese developer Innovent Biologics.
- Drug development cycles typically span 10-15 years.
By The Numbers
3,000
participants
45%
proportion of foreign attendees
$1 billion
deal value
10,000
employees
They Said
"What we are talking about now [referring to geopolitical tensions] is short term. In three or six months, it may look different again."
"China really wants to explore more long term and mutual trust cooperation with Switzerland and Europe. There is a shift in focus from the US to Europe."
1
US Volatility Triggers Eastern Pivot
2
Basel Summit Smashes Records
3
China Sheds 'Copycat' Label
4
Pharma Giants Bet Billions
5